4.6 Review

Cancer and liver cirrhosis: implications on prognosis and management

期刊

ESMO OPEN
卷 1, 期 2, 页码 -

出版社

ELSEVIER
DOI: 10.1136/esmoopen-2016-000042

关键词

-

类别

资金

  1. Austrian Science Fund [J 3747-B28]
  2. National Institutes of Health [P01 CA080124, R01 DK103879]
  3. Austrian Science Fund (FWF) [J 3747] Funding Source: researchfish
  4. Austrian Science Fund (FWF) [J3747] Funding Source: Austrian Science Fund (FWF)

向作者/读者索取更多资源

Liver cirrhosis, the end-stage of every chronic liver disease, is not only the major risk factor for the development of hepatocellular carcinoma but also a limiting factor for anticancer therapy of liver and non-hepatic malignancies. Liver cirrhosis may limit surgical and interventional approaches to cancer treatment, influence pharmacokinetics of anticancer drugs, increase side effects of chemotherapy, render patients susceptible for hepatotoxicity, and ultimately result in a competitive risk for morbidity and mortality. In this review, we provide a concise overview about the impact of liver cirrhosis on the management and prognosis of patients with primary liver cancer or non-hepatic malignancies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据